SLC6A1
Sodium- and chloride-dependent GABA transporter 1
As of the edition of 20 October 2026, SLC6A1 (sodium- and chloride-dependent GABA transporter 1, UniProt P30531) has 1 drug tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30531
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Mental health; Chemically induced; Nervous system
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tiagabine | Marketed | Phase 4 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 2 |
| Total on the list | 2 |